Canada markets open in 6 hours 56 minutes

  • S&P/TSX

    19,779.97
    -11.63 (-0.06%)
     

  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     

  • DOW

    33,963.84
    -106.56 (-0.31%)
     

  • CAD/USD

    0.7415
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    90.52
    +0.49 (+0.54%)
     

  • Bitcoin CAD

    35,240.86
    -587.57 (-1.64%)
     

  • CMC Crypto 200

    558.64
    -9.41 (-1.66%)
     

  • GOLD FUTURES

    1,940.90
    -4.70 (-0.24%)
     

  • RUSSELL 2000

    1,776.50
    -5.33 (-0.30%)
     

  • 10-Yr Bond

    4.4380
    0.0000 (0.00%)
     

  • NASDAQ futures

    14,911.75
    +42.25 (+0.28%)
     

  • VOLATILITY

    17.20
    -0.34 (-1.94%)
     

  • FTSE

    7,683.91
    +5.29 (+0.07%)
     

  • NIKKEI 225

    32,678.62
    +276.21 (+0.85%)
     

  • CAD/EUR

    0.6963
    -0.0002 (-0.03%)
     
MARKET LESSONS:

WHAT A BIG BLACKBERRY WIN CAN TELL YOU ABOUT INVESTING

"I want to emphasize this kind of win is extremely rare," says a portfolio manager

BioCryst to Report First Quarter 2023 Financial Results on May 3

BioCryst Pharmaceuticals, Inc.
·1 min read
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com